Syneron Medical to Report Fourth Quarter 2011 Financial Results on February 9, 2012 |
 |
 |
| Tuesday, 31 January 2012 18:52 |
|
Syneron management will host a conference call and a live webcast at 8:30 a.m. (ET) on the same day. A question & answer session will follow management's discussion of events in the fourth quarter 2011. Investors and analysts may participate in the conference call using the following dial-in numbers: US (toll free): (877) 844-6886 International: (970) 315-0315 The conference passcode for both is 48538831. Investors and other interested parties can also access a live webcast of the conference call through the Investor Overview page on Syneron's website at www.syneron.com. Please log-in at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. About Syneron Medical Ltd. Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets and services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Contact Information Contacts: Asaf Alperovitz Chief Financial Officer + 972 73 244 2283 Email: Email Contact Zack Kubow The Ruth Group 646-536-7020 Email: Email Contact BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
about 14 minutes ago
Stock Market: Stocks Extend Losing Streak http://t.co/ZmZxvJiO
about 1 hour ago
Cancer Survivors Who Exercise Live Longer http://t.co/U4MhX04a
about 2 hours ago
Colon cancer screenings that don’t require laxatives are almost as effective as colonoscopies and may encourage more tests http://j.m…
about 3 hours ago
Testing a Drug That May Stop Alzheimer’s Before It Starts $RHHBY http://t.co/Wjgw15IS
about 3 hours ago
Two patients get eye stem cells transplanted to restore sight http://t.co/HHYZlFFT
about 3 hours ago
US Senate call to scrap drug patents: http://t.co/W1BOuxJp
about 3 hours ago
http://t.co/MAgh4Xke
about 3 hours ago
Eyeing the inflammasome http://t.co/89KnKhiM
Free Phone Trade Alerts
